Question follow-through · 3107
Trastuzumab Deruxtecan
To ask the Secretary of State for Health and Social Care, if he will make representations to (a) Daiichi Sankyo and (b) AstraZeneca following the decision by NICE not to recommend Enhertu as a cost effective treatment for advanced stage breast cancer.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 30 Aug 2024
- Target answer date
- 3 Sept 2024
- Answer
- 9 Sept 2024 · 10 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Coronavirus: Vaccination · 2 Sept 2024
- Cancer: Medical Treatments · 2 Sept 2024
- Cancer: Medical Treatments · 2 Sept 2024
- Cancer: Medical Treatments · 2 Sept 2024
- Respiratory Syncytial Virus: Vaccination · 2 Sept 2024
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
30 Aug 2024
Question tabled
To ask the Secretary of State for Health and Social Care, if he will make representations to (a) Daiichi Sankyo and (b) AstraZeneca following the decision by NICE not to recommend Enhertu as a cost effective treatment for advanced stage breast cancer.
3 Sept 2024
Target answer date
Date supplied by the official written-questions record.
9 Sept 2024
Answer published
Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE), on the basis of an evaluation of a treatment’s costs and benefits. The NICE’...
Official data retrieved 27 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Coronavirus: Vaccination
2 Sept 2024 · To ask the Secretary of State for Health and Social Care, if he will make it his policy to extend the covid-19 booster vaccination this autumn to (a) unpaid and (b) young carers.
Cancer: Medical Treatments
2 Sept 2024 · To ask the Secretary of State for Health and Social Care, whether he (a) has had and (b) plans to have discussions with the National Institute for Health and Care Excellence on (i) its use of the new severity modifier and (ii) how it (A) measures and (B)
Cancer: Medical Treatments
2 Sept 2024 · To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence has made a recent assessment of the potential impact of the removal of the end-of-life modifier on cancer technology appraisals.
Cancer: Medical Treatments
2 Sept 2024 · To ask the Secretary of State for Health and Social Care, how many myeloma patients are receiving a fourth line treatment; and what proportion of those patients are being treated with isatuximab in combination with pomalidomide and dexamethasone.
Respiratory Syncytial Virus: Vaccination
2 Sept 2024 · To ask the Secretary of State for Health and Social Care, what the evidential basis is for not extending the respiratory syncytial virus immunisation programme to all children under the age of one year.
NHS: Training
2 Sept 2024 · To ask the Secretary of State for Health and Social Care, how many applicants were (a) accepted onto and (b) rejected from the NHS Scientist Training Programme in (i) 2021-2022, (ii) 2022-2023 and (iii) 2023-2024.
Prescriptions
2 Sept 2024 · To ask the Secretary of State for Health and Social Care, if he will make it his policy to conduct a review of prescribing rights during this Parliament.
Genomics: Research
3 Sept 2024 · To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effectiveness of (a) Genomics England Limited and (b) the NHS Genomic Medicine Service in (i) stimulating and (ii) facilitating research activity.
Dentistry: Recruitment
3 Sept 2024 · To ask the Secretary of State for Health and Social Care, with reference to the Dental recruitment incentive scheme 2024/25 published on 10 May 2024, how many NHS dentists have been recruited on the Golden Hello pathway in each (a) region and (b) ICB area
Multiple Myeloma: Medical Treatments
3 Sept 2024 · To ask the Secretary of State for Health and Social Care, if he will commission research to (a) track and (b) compare international access to myeloma treatments; whether his Department holds data on the use by other countries of isatuximab in combination
Respiratory Syncytial Virus: Vaccination
12 Sept 2024 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 September 2024 to Question 3791 on Respiratory Syncytial Virus: Vaccination, whether he has received any advice from the Joint Committee on Vaccination and Immunisation
NHS: Training
4 Oct 2024 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 September 2024 to Question 3798 on NHS: Training, how many of the rejected or unsuccessful direct entry applicants were not accepted (a) due to the lack of a suitable p